Get the Stockscreener App
2.76
5.34%
0.14
After Hours:
2.78
0.02
+0.72%
Esperion Therapeutics Inc stock is traded at $2.76, with a volume of 4.59M.
It is up +5.34% in the last 24 hours and down -17.12% over the past month.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
See More
Previous Close:
$2.62
Open:
$2.67
24h Volume:
4.59M
Relative Volume:
0.94
Market Cap:
$708.80M
Revenue:
$403.14M
Net Income/Loss:
$-22.68M
P/E Ratio:
-13.17
EPS:
-0.2095
Net Cash Flow:
$-13.09M
1W Performance:
+10.18%
1M Performance:
-17.12%
6M Performance:
+7.81%
1Y Performance:
+64.29%
1-Day Range:
$2.66
$2.86
1-Week Range:
$2.46
$2.86
52-Week Range:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Name
Esperion Therapeutics Inc
Sector
Phone
734-887-3903
Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.76 | 672.84M | 403.14M | -22.68M | -13.09M | -0.2095 |
TAK
Takeda Pharmaceutical Co Adr
|
18.29 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.71 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.74 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
541.60 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Dec-18-24 | Initiated | Goldman | Neutral |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-20-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-01-23 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Jun-15-23 | Upgrade | BofA Securities | Underperform → Buy |
| Mar-16-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-16-23 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Mar-07-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-27-23 | Resumed | BofA Securities | Neutral |
| Feb-24-23 | Upgrade | Jefferies | Hold → Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-03-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-05-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-10-22 | Initiated | H.C. Wainwright | Buy |
| Oct-19-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-14-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-05-21 | Downgrade | Stifel | Buy → Hold |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-12-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-09-21 | Downgrade | Goldman | Neutral → Sell |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-10-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-29-20 | Resumed | JP Morgan | Underweight |
| Aug-11-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Apr-01-20 | Resumed | BofA/Merrill | Buy |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-24-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-14-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-16-19 | Upgrade | Goldman | Sell → Neutral |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-06-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Apr-26-19 | Upgrade | Goldman | Sell → Neutral |
| Mar-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-07-19 | Reiterated | Needham | Strong Buy |
| Dec-13-18 | Initiated | Goldman | Sell |
| Oct-29-18 | Upgrade | Northland Capital | Market Perform → Outperform |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Aug-17-18 | Upgrade | Citigroup | Neutral → Buy |
| Jul-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-03-18 | Downgrade | JP Morgan | Neutral → Underweight |
| May-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
View All
Esperion Therapeutics Inc Stock (ESPR) Latest News
Dip Buying: Does Esperion Therapeutics Inc align with a passive investing strategy2026 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion acquires Enbumyst maker Corstasis - MSN
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics prices $75M public offering - MSN
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Insider Monkey
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock - MarketBeat
Esperion Therapeutics CFO Halladay sells $17k in stock By Investing.com - Investing.com India
Esperion Therapeutics CEO Koenig sells $69,546 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Halladay sells $17k in stock - Investing.com
Esperion (NASDAQ: ESPR) CLO sells 5,708 shares to cover RSU tax bill - Stock Titan
Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CFO sells shares to cover taxes on vested RSUs - Stock Titan
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 7.6%Here's What Happened - MarketBeat
Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
ESPR (NASDAQ: ESPR) affiliate files to sell 6,424 vested shares after vesting - Stock Titan
ESPR (NASDAQ: ESPR) Form 144 files planned sale of 5,708 shares - Stock Titan
Sheldon Koenig to sell 25,578 ESPR shares (NASDAQ: ESPR) under Form 144 - Stock Titan
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - Bitget
Esperion to Present Two New Analyses From CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - 富途牛牛
CLEAR Outcomes trial findings to be presented by Esperion Therapeutics at major cardiology event - Traders Union
Bempedoic acid data spotlight statin-intolerant, autoimmune patients - Stock Titan
BofA reiterates Esperion Therapeutics stock Underperform rating By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) CFO receives major equity grants - Stock Titan
Esperion (ESPR) CLO receives new stock and option grants - Stock Titan
[Form 4] Esperion Therapeutics, Inc. In... - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 7.8% Following Analyst Upgrade - MarketBeat
2026 cholesterol guideline backs bempedoic acid for statin-intolerant patients - Stock Titan
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - Sahm
Operating cash flow per share of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference - MarketBeat
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Integral Health Asset Management LLC Purchases New Stake in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics (NASDAQ:ESPR) Price Target Raised to $5.00 - MarketBeat
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - TradingView
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
Esperion Therapeutics Inc Stock (ESPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.12%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):